Trials / Recruiting
RecruitingNCT06937112
18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
Clinical Application of a Novel 18F Labeled Fibroblast Activation Protein (FAP) Targeted Molecular Probe in Early Tumor Diagnosis
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Nanjing First Hospital, Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the safety of the novel FAP targeted molecular probe 18F-FAPI-YQ104 labeled with radioactive isotopes in clinical applications and verify its effectiveness in tumor diagnosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | PET-CT examination | Intravenous injection of 18F-FAPI-YQ104 for PET-CT examination |
Timeline
- Start date
- 2025-04-10
- Primary completion
- 2026-01-31
- Completion
- 2026-03-31
- First posted
- 2025-04-22
- Last updated
- 2025-04-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06937112. Inclusion in this directory is not an endorsement.